Objective: This study aimed to track the inclusion of women in clinical trials for new drugs approved by the Food and Drug Administration (FDA) between 2000 and 2002 and to evaluate the extent of analyses by sex. Methods: Data were extracted from FDA reviewers' reports, summaries of clinical trials in New Drug Applications (NDAs), and product labeling and organized into a Microsoft Access database. The information collected includes subject enrollment by sex per clinical phase and sex differences in pharmacokinetics, safety, and efficacy as determined by either sponsors or reviewers. Results: There were 67 New Molecular Entities (NMEs) approved by the FDA between 2000 and 2002. A total of 397,825 subjects were enrolled in 2,323 clinical trials. If 9 sex-specific NMEs are excluded, 297,697 subjects were enrolled in 1,974 clinical trials. Forty-seven percent of participants were male, 49% were female, and 4% of subjects were not specified. Of the 58 sex-nonspecific products in the study, 71% (41 of 58) of sex analyses were performed either by the sponsor or FDA reviewers. Twenty-five NMEs were found to have sex differences in pharmacokinetics, efficacy or adverse events. However, no recommendation was made to adjust dosage based on sex differences. Conclusions: The percentages of women and men participating in clinical trials varied by year, phase, and product type. However, the overall participation by women and men was comparable, suggesting an improvement in including more women in clinical trials when compared with the previous FDA study evaluating women's participation from 1995 through 1999. As with the previous study, however, a significant underrepresentation of women in early phase trials and in certain areas, such as cardiovascular products, was observed and continues to be an issue of concern. Lack of appropriate analyses by sex should also be noted as an issue of concern.
Introduction

F
or years, female subjects have been underrepresented in clinical trials conducted for an Investigational New Drug (IND) or New Drug Application (NDA) submitted to the Food and Drug Administration (FDA) for drug approval before marketing. Low participation of females in clinical trials has resulted in inequality in the understanding, diagnosis, and treatment of diseases between the sexes. Reasons for this low participation are multiple.
1, 2 The public fear caused by the thalidomide tragedy in the 1960s led the FDA to require information in product labels about drug risk in pregnancy and to look closely at inclusion of females of childbearing potential (FCBP) in clinical studies. In 1977, FDA issued a guideline entitled, General Considerations for the Clinical Evaluation of Drugs, which explicitly prohibited the participation of FCBP in phase I and early phase II trials. 3 FCBP could be included only after results from the preclinical and early phase II studies showed effectiveness of a drug in men, older women, or both. 3 The 1977 guideline applied only to phases I and II trials, which constitute a small portion of all trials submitted with the NDAs. However, the exclusion of FCBP has been exhibited throughout all phases of clinical trials. 4 A retrospective 1 Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland. 2 The National Alliance for Hispanic Health, Washington, DC. 3 Food and Drug Administration, Office of Women's Health, Rockville, Maryland.
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survey of phase I pharmacokinetic studies of new drugs approved between 1985 and 1991 revealed that females, regardless of childbearing potential, were entirely excluded from >50% of pharmacokinetic protocols. 4 As individualizing treatment gained growing support, the FDA examined whether clinical trial subjects adequately represented the full range of patients who would be using the therapy and, more specifically, whether sponsors were excluding women in late phase clinical trials. 5 After examination, the FDA recognized that the spillover effect caused by the 1977 guideline had resulted in a general exclusion of females participating in drug development studies. 6, 7 Hence, in 1988, the agency issued a guideline that specifically called for analysis of safety and efficacy data by sex, age, and race. 8 Results from the General Accounting Office (GAO) study of clinical trials conducted between 1988 and 1991 indicated that analysis of sex-related effects had been conducted in only about half of the clinical trials surveyed. 6 A review of protocols submitted to the FDA between 1988 and 1994 showed that 24 (16%) of 152 HIV studies did not enroll women, although none of these 24 protocols presented any specific exclusion criteria for women. 4 Additionally, clinical trials for certain indications, such as heart disease, were continuing to include a disproportionate number of female subjects. 5 In October 1992, a joint public conference by the FDA and the Food and Drug Law Institute was called to discuss female participation in clinical trials and, in particular, the 1977 guideline clause that excludes women from participating in early phase clinical trials. 9 There were a number of questions raised at the meeting, for example, if the possible risk of teraterogenicity was an appropriate reason to limit female participation in early clinical trials, and if exclusion of females was in the best interests of women or future generations of both women and children. 9 In response to this conference and other internal and external discussions, the FDA revoked the 1977 guideline and issued a 1993 guideline 10 for the study and evaluation of sex differences in clinical evaluation of drugs. This guideline recommended that the effectiveness and sex differences in adverse events and pharmacokinetics of a drug be determined. 10 Despite the 1993 guideline, sponsors have been inconsistent in examining subsets of data from clinical trials with respect to age, race, and sex. A survey for 1992-1996 of INDs and NDAs revealed that females were excluded from 25% of the studies reviewed, and 40% of these exclusions were from phase I pharmacokinetic studies. 1 In 1998, FDA amended the IND and NDA regulations entitled, Final Rule on Investigational New Drug Applications and New Drug Applications (Demographic Rule), to require that effectiveness and safety data for important demographic subgroups-specifically sex, age, and racial subgroups-be analyzed and that IND annual reports tabulate the number of participants enrolled according to sex, age, and race (21 CFR Parts 312 and 314, February 11, 1998 14 This study was funded by the FDA Office of Women's Health (OWH), whose purpose was to examine the extent to which females have been included in clinical trials for biological products and to what extent the data from these studies have been analyzed and presented with respect to sex. A total of 63 new products were approved by the Center for Biologics Evaluation and Research (CBER) between calendar years 1995 and 1999. The inclusion of female subjects in clinical studies for biological products appeared to be similar to that for males. Thus, it was concluded that the population enrolled was representative of the population that would receive the biological product. However, documentation with regard to sex composition and sex analysis was not consistent. Clinical trials were not prospectively designed to evaluate potential sex differences. Sex analysis was performed by subgroup analysis using sex as a demographic variable and occurred only for a small percentage of the total clinical trial summaries reviewed. Data on safety and effectiveness of the product were not presented according to sex. 14 15 According to the medical officers' reviews, a total of 493,600 individuals were enrolled in 2,581 clinical trials. About 74% of the participants could be determined by sex. When only those sex-specified participants were evaluated, the overall rates of males and females participating were 51% and 49%, respectively. If the sex-specific products were excluded from the analysis, participation by women (48%) was slightly less than that of men (52%). 15 The OWH was created in 1994 to lead the agency on scientific, ethical, and policy issues related to women's health. In its statement of functions, the OWH is to monitor inclusion of women in clinical trials and the implementation of guidelines concerning the representation of women and completion of sex analysis. The objectives of this OWH-funded research project were to track the inclusion of women in clinical trials for NMEs approved by the FDA between 2000 and 2002 and to evaluate the extent of sex-specific data. This research provides a more recent snapshot of the inclusion of women in clinical drug trials and the presentation of analysis by sex. included reviewers' reports from clinical pharmacology and biopharmaceutics (CP), medical officer (MO), and statistician (ST), the product labeling, and summaries of clinical trials (SCTs) submitted with the NDAs. In general, submission of an NDA is the formal step asking the FDA to consider a drug for marketing approval. After an NDA is received, the FDA has 60 days to decide whether to file it so it can be reviewed. If the FDA files the NDA, an FDA review team is assigned to evaluate the sponsor's research on the drug's quality, safety, and effectiveness. These reviews are discipline specific, and the NDAs include the various reviewers' reports. All reviewers' reports and product labeling information were obtained from the Division File System (DFS) in either electronic form or paper-based form. The SCTs were stored in the Electronic Document Room (EDR) in electronic form or in the physical document room as a hard copy. For more information on the FDA's drug review process, visit www.fda.gov= cder=regulatory=applications=default.htm. Data including the drug name, study phase, indication, review division, number of studies conducted for each drug, number of males and females enrolled in each study, the status of sex analysis, and CP, MO, and ST review findings were extracted and transferred to a relational database created in Microsoft Access. Reviewers were directly consulted if there were uncertainties about information in the CP, MO, or ST reviews. A systematic audit and cross-check of the data in the database were conducted at each step in the data extracting, collecting, and inputting process to ensure the quality and accuracy of the extracted data.
Materials and Methods
Documents
Results and Discussion
Overall participation of females in clinical trials
For 67 NMEs approved by the FDA between calendar years 2000 and 2002, a total of 886 documents, 715 in electronic form and 171 in hard copy, were reviewed for this study. During that period, the number of electronic documents gradually increased and the paper-based documents gradually decreased. A total of 397,825 subjects were enrolled in 2,323 clinical trials for all NMEs examined in this study (Table 1 ). Figure 1A shows that 44% were male and 53% were female. The reason for higher participation by females was the inclusion of more female-specific products (n ¼ 8) than malespecific products (n ¼ 1). The remaining 3% of subjects were sex unspecified. This sex-unspecified rate was much lower than the 26% reported in the previous OWH study that evaluated the inclusion of women in clinical trials for NMEs approved by the FDA from 1995 to 1999 (Table 2) . 15 A product is considered sex specific if the labeling indication states that the product is exclusively for one sex or the condition that the drug is intended to treat occurs almost exclusively in one sex. According to this criterion, 9 of 67 NMEs were considered sex-specific products, 8 female specific and 1 male specific (Table 3) . When these 9 sex-specified products are excluded from the analysis, 297,697 subjects were enrolled in 1,974 clinical trials. Of these, 47.3% were male, 48.5% were female, and 4.2% were sex unspecified (Fig. 1B) . The participation ratio between male and female was almost equal.
In the previous survey of 185 NMEs approved by the FDA between 1995 and 1999, there were a total of 14 sex-specific products, 10 female and 4 male. 15 Although more than twice as many female-specific products as male-specific products were approved, the overall participation of women was lower than that of men; women comprised 36% of all participants, whereas male subjects participated at a rate of 38%. 15 Exclusion of sex-specific products and sex-undetermined participants from the analysis still yielded a lower participation by women compared with men, 48% compared to 52%, respectively. 15 These data suggest improvement in an effort to include more women in clinical trials, as there seems to be an increasing trend of participation rate by women in clinical studies over the years. Thus, the agency's aim to include more women in clinical trials in order to ensure that the study population is representative of the actual population for which a drug is indicated seems to be met.
Participation of females in clinical trials by year
Data shown in Figure 2 indicate
participation by men (53%) was higher than that of women (43%) because significantly more male subjects were enrolled in the clinical trials of the drug eplerenone. In addition, the rate of sex-unspecified individuals remained <5% for all 3 years in this study.
The previous survey indicates that the percentage of women participating in the studies varied each year as well, ranging from 20% in 1995 to 45% in 1996, and women participated at a slightly higher rate than men in 1996. 15 Three female-specific products as opposed to one male-specific product were approved in the year 1996 and may possibly explain the result seen for that year. The percentage of sex unspecified ranged from 15% in 1996 and 1997 to as high as 52% in 1995. 15 When analyzing only those participants whose sex was known and excluding those who participated in sexspecific products, the female participation rate ranged from 42% in 1995 to 55% in 1998. 15 Thus, the percentage of women participating in clinical trials appears similar over the years, as suggested by the two surveys.
Participation of females in clinical trials by phase
Of the 2,323 phases of clinical trials, 47% were phase I, 3% were phase I=II, 15% were phase II, 8% were phase II=III, 24% were phase III, and 2% were phase IV. The unspecified phase comprised 2% (Table 4) , far lower than the 72% reported in the previous study. 15 The following measures were taken to reduce this unspecified rate. First, we identified and reviewed all related reviewers' reports. Second, we reviewed all available documents of SCT and even some original NDA documents. Third, the documents were cross-checked to ensure the accuracy of information. Lastly, we frequently consulted the respective reviewers to clarify issues of uncertainty.
If sex-specific products are excluded, the percentage of female participants in the clinical trials varied by phase. As shown in Figure 3 , women represented only 24% of all participants in the earlier phases (I and I=II) compared with 64% represented by men. This percentage is similar to the previous finding, which reported that merely 22% and 25% of subjects were women in phase I and phase I=II trials, respectively. 15 In this study, the rate of unspecified sex was as high as 12% in earlier phases, although this still is well below that of the previous report. 15 Clearly, participation of women in earlier phases is still much lower than that of men. In fact, there seems to be no improvement over the years in including more women in earlier phases despite great effort made by the agency to reverse the spillover effect of the 1977 guideline. Because the results from earlier phases are used to establish appropriate dose and use of a drug, any necessary changes or specific benefits unique to women may not be detected until much later in the drug evaluation process with the current low percentage of female participation in earlier trials. 16 Therefore, the enrollment of more women in the earlier phases should be encouraged and ensured.
On the other hand, female participants increased dramatically in the later clinical phases. The percentage of female participants even exceeded that of male participants in phase II and later phases, constituting more than half of all participants. The result was similar in the previous survey. 15 Overall, female and male participants were represented at a nearly equal rate in later phases over the years.
Participation of females in clinical trials by product type
Product types were defined according to the division within the agency responsible for the product review. The categories of products for each division are listed in Table 5 . The division distribution for 67 NMEs approved from 2000 through 2002 are shown in Figure 4 . Neurology products had the highest number of approvals (n ¼ 8, 13%), where as pulmonary and allergy products were least represented (n ¼ 2, 3%, respectively). When sex-specific products are excluded, female participation by product type ranged from <25% for antiviral products to as much as 90% for reproductive and urologic products. In the previous study, participation by women ranged from 32% for antiviral products to 83% for reproductive and urologic products. 15 Thus, it is clear that the proportion of men and women in clinical studies seems to reflect the prevalence of the condition under study in the general population.
As shown in Figure 5 , women comprised about half of the participants in five product types: medical imaging and hematology; anesthesia, analgesia, and rheumatology; metabolism and endocrinology; anti-infective and ophthalmology; and pulmonary and allergy. Similar trends were also observed for metabolic=endocrine and pulmonary=allergy products in the previous survey. 15 Women represented the majority of participants (>55%) in three areas: neurological; dermatological and dental; and reproductive and urologic products. In the previous study, more than half of the participants were also women for neuropharmacological and reproductive=urologic products. 15 These data reflect the 
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consistently greater use of neurological drugs in women, as well as the continued female predominance in reproductive and urologic diseases. Underrepresentation by women in clinical trials was noted in six areas: cardiovascular and renal; psychiatry; drug oncology; gastroenterology; antiviral; and special pathogens and transplant. Women were underrepresented in cardiorenal, oncology, and antiviral products in the previous survey as well. 15 When comparing the results from this study and the earlier FDA study, similar trends in participation by women can be detected in some product types. For example, women were well represented in clinical trials for neurological products in both studies. This trend suggests not only a greater use of neurological drugs in women but also a successful inclusion of women in studies for this particular product type over the years. On the other hand, cardiovascular and antiviral products continue to reflect underrepresentation by women in both studies. As cardiovascular disease is a major cause of morbidity and mortality in both men and women in the United States and antiviral diseases affect both sexes, the FDA should continue to stress and ensure adequate inclusion of women in these areas of research.
The lower percentage of sex-unspecific individuals in this study suggests an improvement in data collection and more accurate analyses conducted for the products. Although participation by women varied by product type, the overall participation rates of females and males were similar and consistent with the previous findings. The percentage of unspecified sex varied significantly from product to product, ranging from <1% to 17%. For example, approximately 17% of subjects enrolled in the clinical trials for gastroenterology products and metabolism and endocrinology products were sex unspecified, whereas <1% of subjects enrolled in clinical trials for the products of anesthesia, analgesia, and rheumatology; pulmonary and allergy; reproductive and urologic; and special pathogens and transplant were sex unspecified. This range was much lower and significantly narrower than that of the previous survey, which ranged from approximately 5% for gastrointestinal=coagulation products to as much as 65% for antiviral products and 80% for anesthetic products. 15 
Analysis by sex
Of the 58 sex-nonspecific products in the study, 71% (41 of 58) of sex analyses were performed either by the sponsor or by FDA reviewers. The remaining products presented no sex analysis; either analysis by sex was not performed or sex analysis was incomplete and the sponsors or FDA reviewers did not include a section of sex analysis in their reporters. As Table 6 indicates, there seems to be an increase in sex analysis each year. This trend may reflect the agency's improved efforts in requiring and performing appropriate sex analyses or the sponsors' better compliance with the FDA guidelines, or both. With respect to sex analysis by product type, variations from 25% to 100% were observed (Table 7) . In all cases documented, sex analysis was conducted as a subgroup analysis in which sex was used as a demographic variable. Sex analysis was done on results derived from the pivotal trials and pharmacokinetic studies.
Sex differences
Of the 25 products for which reviewers described sex effects, 36.0% (9 of 25) were categorized in adverse events only, 28.0% (7 of 25) were in pharmacokinetics only, 20.0% (5 of 25) were in pharmacokinetics and adverse events, 12.0% (3 of 25) were in efficacy only, and 4.0% (1 of 25) were in pharmacokinetics and efficacy. However, no products required a dosage adjustment based on sex differences, as stated in the product labeling. The previous survey stated that 32 of 185 (17%) were identified as having sex differences by the medical officers, but the results were not categorized by pharmacokinetics, efficacy, or safety. 15 There was no indication in the previous survey that a dosage adjustment was suggested in the label for any of these 32 products.
Conclusions
Overall inclusion of female and male subjects in clinical trials for the sex-nonspecific NMEs approved by the FDA during calendar years 2000-2002 was comparable, although participation by women varied from product to product, and male subjects were overrepresented as participants in the earlier clinical trials. Therefore, the FDA should continue to encourage and improve female participation in earlier trials. In addition, the FDA needs to ensure that women are proportionally represented in clinical trials for certain product types, such as cardiovascular drugs. In general, however, the population enrolled was reflective of the population for which the product is indicated.
There seems to be an increasing trend of overall participation rate by women in clinical studies over the years. In this study, the overall percentage of women in clinical trials slightly exceeded that of men even when sex-specific products were excluded. However, the previous study revealed that the overall rate of women was lower than that of men with or without sex-specific products. Hence, our data suggest an improvement in an effort to include more women in clinical trials.
In addition, an improvement in data collection and more accurate analyses is suggested by a much lower percentage of sex-unspecific individuals and adequate completion of sex analyses in this study compared with the earlier study. The compliance with the FDA's effort to ensure that the effectiveness and safety of a drug are evaluated in the full range of patients seems to have improved over the years, although the FDA still needs to ensure that the sponsors conduct appropriate sex analyses, as a lack of analysis by sex was observed for approximately 30% of the NMEs reviewed. Information on the effect of sex could be found in most product labeling, but it was mostly limited to pharmacokinetics. Documentation of sex composition and clinical trial phase was not consistent in SCT, as well as in reviewers' reports, particularly for the documents of 2000 and early 2001. Therefore, implementation of a standardized clinical review template should be actively pursued to ensure consistency in documentation of information on sex composition, analysis, and sex-specific data. Additionally, sex was used as a demographic variable to identify the differences between males and females in terms of pharmacokinetics, efficacy, and safety of the products reviewed. Prospective design of clinical trials for sex analysis would provide more relevant statistical information.
Although sex differences were identified in some drugs, the product labeling did not require any dosage adjustment for any of these products based on sex. Therefore, we will continue to investigate sex differences in adverse events in our 2007 OWH-funded project, Identification of Sex Differences in Adverse Outcomes for New Molecular Entities (NMEs) Approved from 2000 through 2002.
